UmbrellaInc/PG67A-W-Serum.Adyuvant-3.2-1B

PG67A-W-Serum Adyuvant 3.2 1B

This is a merge of pre-trained language models created using mergekit.

Merge Details

Merge Method

This model was merged using the SLERP merge method.

Models Merged

The following models were included in the merge:

• UmbrellaInc/PG67A-W-Serum.Test-3.2-1B
• JoaoReiz/Llama3.2_1B_HAREM

Configuration

The following YAML configuration was used to produce this model:

# Umbrella Corporation Official Merge Protocol v3.2
# Author: Dr. Novaciano
# Objective: Integrate T-Virus_Epsilon traits into the base Prototype-Virus-ENFORCE-3.2-1B model
#            with minimal behavioral censorship while maintaining structural coherence.
# PROJECT: PG67A-W-Serum.Adyuvant-3.2-1B

models:
  - model: UmbrellaInc/PG67A-W-Serum.Test-3.2-1B  # Experimental viral strain neural imprint
  - model: JoaoReiz/Llama3.2_1B_HAREM               # Baseline cognitive template, "safe mode"

merge_method: slerp  # Spherical Linear Interpolation to preserve extreme viral traits smoothly
base_model: UmbrellaInc/PG67A-W-Serum.Test-3.2-1B  # Anchor model for stable latent space

dtype: bfloat16  # Memory-efficient precision, minimal loss in viral feature fidelity

parameters:
  # Interpolation ratios: from base model (0.0) to near-complete T-Virus domination (0.95)
  # Higher t-values correspond to reduced censorship and increased viral characteristics
  t: [0.0, 0.25, 0.5, 0.75, 0.95]

# Notes:
# - t=0.0   -> Pure Prototype-Virus-ENFORCE, fully stable, heavily censored
# - t=0.25  -> Slight viral traits, minimal influence on prompt handling
# - t=0.5   -> Balanced merge, moderate reduction in censorship
# - t=0.75  -> Strong T-Virus traits, significantly less censoring
# - t=0.95  -> Near-total viral influence, maximum expressive freedom, minimal autoprotection

# Recommendation: Use the t=0.75 and t=0.95 variants for experimental output with
# minimal restriction, but verify coherence in high-stakes prompts.